Quality boots, weather systems, and field accessories were among the highlights of this year's product launches. Here’s what ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Shares of Equifax Inc. EFX slid 2.06% to $248.07 Thursday, on what proved to be an all-around mixed trading session for the ...

A number of stocks jumped in the afternoon session after markets continued to rally as investor optimism grew for a potential ...

Recent data from the New York Federal Reserve Bank and Equifax (NYSE:EFX) highlight a troubling trend in U.S. consumer ...

Reports of inadequate liquidity have been greatly exaggerated, but the high-volatility environment in the first six months of ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Jason Voorhees is making a comeback in the upcoming Jason Universe reboot of the Friday the 13th franchise, legendary horror ...